Antares Pharma (ATRS) Tops Q4 EPS by 1c

Antares Pharma (NASDAQ: ATRS) reported Q4 EPS of ($0.03), $0.01 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.2 million versus the consensus estimate of $11.25 million.

For earnings history and earnings-related data on Antares Pharma (ATRS) click here.

You May Also Be Interested In

• Rent the Runway (RENT) Reports Q2 Loss of $0.38/sh
• Chewy (CHWY) Reports In-Line Q2 EPS, Offers Guidance
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says